Project description
Regulatory T cell based predictive biomarkers of cancer immunotherapy response
The advent of immune checkpoint inhibitors (ICI) targeting regulatory pathways in T cells to ignite antitumour immune responses has revolutionised cancer immunotherapy. However, a significant proportion of patients do not develop a response, or it is accompanied by life-threatening autoimmunity, manifesting as immune-related adverse events (irAEs). Predictive biomarkers of clinical responses and new therapeutic strategies to harness antitumour immunity represent an urgent unmet need. The regulatory T cells (Tregs) are a subpopulation of T cells that modulate the immune system responses. The EU-funded RegSign project will create a 'liquid biopsy' of Tregs for the prediction of ICI efficacy and development of irAEs. Decoding Tregs' signatures in cancer will lead to predictive biomarkers and novel targets for cancer immunotherapy.
Fields of science
Programme(s)
Topic(s)
Funding Scheme
ERC-STG - Starting Grant
Host institution
115 27 Athina
Greece
See on map
Beneficiaries (1)
115 27 Athina
See on map